NeoPlas Innovation
- Company typePrivate
- Founded2001
- HeadquartersFranklin, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
NeoPlas Innovation firmographics
Firmographics- Name
- NeoPlas Innovation
- Legal name
- NeoPlas Innovation
- Website
- https://neoplas.org
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
NeoPlas Innovation industry classification
Industry- Product category
- Specialty Oncology Services
- NAICS
- Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Oncology & Specialty Therapeutics (HLAMAEAJ), Genitourinary Oncology (HLAKAFAM), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where NeoPlas Innovation is headquartered
LocationHeadquarters
- HQ city
- Franklin
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeoPlas Innovation business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Patient Treatment Services: The company operates as a clinical medical practice generating revenue through patient fees for consultations, treatment planning, and ongoing care. Services include initial consultation visits, preliminary conferences, and ongoing treatment oversight. The practice emphasizes fair and accessible pricing, with discounts for prompt payment, 40% reduction for patients certified by charitable organizations, and flexible payment terms (21 days following visits). The company does not accept government or industry funding.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Professional services/ project-based | Pay-as-you-go | Standard patient fees for medical services |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels10 records
NeoPlas Innovation product offering
Product offeringCore offering
NeoPlas Innovation is a clinical cancer treatment and medical consulting practice that delivers an outpatient combination immunotherapy cancer treatment program protected by US Patent 9,034,310. The program combines low-dose interferon alfa-2b and lovastatin with additional agents as needed (cimetidine, capecitabine, temozolomide, hydroxychloroquine), customized per patient, and is supported by initial consultations, preliminary conferences, and ongoing monitoring. The same combination approach is also offered for veterinary oncology patients.
Product overview
NeoPlas Innovation offers a patented combination immunotherapy cancer treatment program (US Patent 9,034,310, May 2015) as its core offering. The treatment combines low-dose interferon alfa-2b and lovastatin as the foundation, with additional agents (cimetidine, capecitabine, temozolomide, hydroxychloroquine) customized for each patient. This outpatient treatment is supported by Initial Consultation and Preliminary Conference services. The company also provides veterinary applications for dogs and horses using the same treatment approach.
Differentiator
Problem solved
Functional benefit
Products and services
- Combination Immunotherapy Cancer Treatment Program Patented outpatient combination immunotherapy treatment (US Patent 9,034,310) for aggressive malignancies using FDA-approved off-label medicines — low-dose interferon alfa-2b and lovastatin as primary agents, with cimetidine for most patients, and optional addition of capecitabine, temozolomide, or hydroxychloroquine, customized per patient. Intended for adults with aggressive or treatment-resistant cancers.
- Initial Consultation Service Comprehensive new-patient consultation service of at least 1.5 hours covering medical history review, physical exam, eligibility evaluation, and treatment planning, intended for prospective patients seeking the combination immunotherapy program.
- Preliminary Conference Low-cost discussion appointment for prospective patients seriously considering the treatment but not yet certain it is the right choice, providing an economical way to learn about the program and determine suitability.
- Veterinary Cancer Treatment Applications Off-label application of the same patented combination immunotherapy technique to veterinary oncology patients, particularly dogs and horses with various cancers.
Companies that use NeoPlas Innovation
Customer profileSegments3 records
Ideal customer profiles3 records
NeoPlas Innovation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NeoPlas Innovation partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Licensed Pharmaceutical FirmmajorIn May 2018, the underlying patent (US Patent 9,034,310) was licensed to a pharmaceutical firm with plans to fully develop its potential. This represents a major step toward research and development goals. The pharmaceutical firm intends to bring the treatment through formal clinical trials and potential broader development. The specific name of the pharmaceutical firm is not disclosed in the source material.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
NeoPlas Innovation competitors and assessment
Company assessmentDirect peers
- Burzynski Clinic: Houston-based alternative cancer clinic offering off-label/investigational drug protocols with proprietary regimens for aggressive and treatment-resistant cancers. Comparable to NeoPlas as a single-site, founder-led practice using non-standard combination regimens outside of formal clinical trials.
- Issels Medical Center: Santa Barbara-based integrative immunotherapy clinic founded in 1951, treating late-stage and treatment-resistant cancers with proprietary combination protocols. Comparable as a founder-driven specialty practice offering immunotherapy-based regimens to patients who have exhausted standard options.
Broad incumbents
- Cancer Treatment Centers of America (City of Hope): National network of specialty oncology hospitals (now part of City of Hope) offering integrative and advanced cancer care. Comparable as a multi-site oncology specialty provider serving patients seeking alternatives to standard community oncology care.
- MD Anderson Cancer Center: Premier academic cancer center running extensive immunotherapy clinical trials including novel combinations and off-label protocols. Comparable as a high-volume oncology destination that draws patient referrals from across the US and internationally.
- Bristol-Myers Squibb (Opdivo): Developer of nivolumab (Opdivo), the leading anti-PD-1 checkpoint inhibitor approved across multiple tumor types including melanoma. Comparable as a dominant immunotherapy player in the same disease categories NeoPlas treats, representing the standard-of-care alternative for many of its target patients.
- Merck (Keytruda): Developer of pembrolizumab (Keytruda), the leading anti-PD-1 checkpoint inhibitor widely used in melanoma and other cancers NeoPlas treats. Comparable as a broad oncology immunotherapy incumbent that has shifted first-line expectations for many of the cancers NeoPlas addresses.
Emerging players
- Iovance Biotherapeutics: Clinical-stage biotech developing tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors including melanoma. Comparable as a developer of cellular/immunologic interventions for treatment-resistant cancers, addressing a similar patient need via a different mechanism.
- NantHealth / NantWorks: Patrick Soon-Shiong's integrated oncology platform combining molecular profiling, combination immunotherapy, and care delivery. Comparable as a developer of multi-mechanism combination cancer regimens and integrated delivery, but at significantly broader scale and with institutional backing.
Others
- Foundation Medicine: Molecular diagnostics company profiling tumors to guide targeted therapy selection. Comparable as an enabling/adjacent service in precision oncology that supports treatment selection for patients with aggressive cancers, including those who would consider NeoPlas protocols.
- Champions Oncology: Oncology services company providing patient-derived xenograft (PDX) testing and translational oncology platforms. Comparable as a service provider in personalized cancer treatment research, intersecting with the precision-medicine narrative that supports NeoPlas's customized protocol approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NeoPlas Innovation social profiles
Digital presenceNeoPlas Innovation financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeoPlas Innovation leadership team
Management profileNumber of profiles
Profiles1 record
NeoPlas Innovation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeoPlas Innovation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeoPlas Innovation
What does NeoPlas Innovation do?
NeoPlas Innovation is a clinical cancer treatment and medical consulting practice that delivers an outpatient combination immunotherapy cancer treatment program protected by US Patent 9,034,310. The program combines low-dose interferon alfa-2b and lovastatin with additional agents as needed (cimetidine, capecitabine, temozolomide, hydroxychloroquine), customized per patient, and is supported by initial consultations, preliminary conferences, and ongoing monitoring. The same combination approach is also offered for veterinary oncology patients.
Is NeoPlas Innovation a public or private company?
NeoPlas Innovation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeoPlas Innovation founded?
NeoPlas Innovation was founded in 2001. It employs 11 to 50 people.
Where is NeoPlas Innovation based?
NeoPlas Innovation is headquartered in Franklin, United States, in the North America region.
How does NeoPlas Innovation make money?
One revenue line is on record: patient Treatment Services.
Who are NeoPlas Innovation's main competitors?
Direct peers on record are Burzynski Clinic and Issels Medical Center. Broad incumbents are Cancer Treatment Centers of America (City of Hope), MD Anderson Cancer Center, Bristol-Myers Squibb (Opdivo) and Merck (Keytruda). Emerging players are Iovance Biotherapeutics and NantHealth / NantWorks. Others are Foundation Medicine and Champions Oncology.
Does NeoPlas Innovation have an API?
No public API is recorded for NeoPlas Innovation.
What industry is NeoPlas Innovation in?
NeoPlas Innovation's product category is Specialty Oncology Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAMAEAJ, Oncology & Specialty Therapeutics. Its NAICS code is 6215 and its SIC code is 8011.